The ribbon-cutting ceremony will be attended by Cryoport clients, governmental dignitaries and business partners. The new Global Logistics Center is located at Parellaan 18, 2132 WS Hoofddorp, near the Schiphol Amsterdam Airport, which serves as The Netherland's main aviation hub for international air traffic.
Opening this new state-of-the-art Global Logistics Center in Amsterdam strategically adds to Cryoport’s global network supporting the distribution of biopharmaceutical products requiring exacting temperature and condition controls. Cryoport’s “Chain of Compliance™” processes will be employed at the new facility, which was built so that it can be rapidly scaled to support additional demand for services. Cryoport clients, including Gilead Sciences, Novartis, Bellicum Pharmaceuticals, Immatics, Janssen Pharmaceuticals, and others, will benefit from Cryoport’s new Global Logistics Center.
Amsterdam is a world-leading hub for the life sciences industry as a result of the region’s many cutting-edge researchers, startups and collaborations, favorable import and export environment, and significant transit infrastructure. In January 2019, the European Medicines Agency moved its headquarters to Amsterdam, joining other major institutes including The Netherlands Cancer Institute and the Sanquin Blood Supply Foundation. Amsterdam supports the life sciences industry in many ways including the Amsterdam Science Park, an incubator for the development of healthcare businesses and special support of areas around the Schiphol Amsterdam Airport and the Port of Amsterdam, which offers strategic logistics hub locations.
Jerrell Shelton, Chief Executive Officer of Cryoport, commented, “The demand for comprehensive global support of regenerative therapies is growing rapidly. We are happy to add Amsterdam to our global network with its excellent connectivity and reputation as one of Europe’s leading life sciences hubs. Choosing this strategic location for our newest Global Logistics Center allows us to more effectively support our global biopharmaceutical client base throughout the research, clinical and commercialization phases of their revolutionary regenerative therapies. We would also like to thank the Dutch regulatory officials who worked so effectively to accommodate and welcome us to Amsterdam.”